Substrates for peptidase A02.002: HIV-2 retropepsin
Peptide and protein substrates that are thought to be physiologically relevant are indicated by P. Peptide and protein substrates that are thought to be pathologically relevant are indicated by D. Peptide and protein substrates that are not physiologically relevant are indicated by N. Synthetic substrates are indicated by S. Click on the symbol to show only physiological, non-physiological or synthetic substrates, or here to display all substrates. How cleavage sites have been identified are indicated by the following evidence codes: NT = N-terminal sequencing, MS = mass spectroscopy, MU = mutation, CS = consensus sequence, LC = liquid chromatography. To see all annotated cleavages for a protein substrate, click on the UniProt Accession.
| Substrate | Uniprot | Residue range | Cleavage Site | Cleavage type | Evidence | P4 | P3 | P2 | P1 | P1' | P2' | P3' | P4' | Reference | CutDB | MERNUM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| actin, alpha cardiac muscle 1 | P68032 | 3-377 | peptide-Gly270+Met-peptide | N | Ser | Phe | Ile | Gly | Met | Glu | Ser | Ala | Tomasselli et al., 1991 | 26111 | ||
| calmodulin | P62157 | 2-149 | peptide-Asn171+Tyr-peptide | P | Gly | Gln | Val | Asn | Tyr | Glu | Glu | Phe | Tomasselli et al., 1991 | 26103 | ||
| calmodulin | P62157 | 2-149 | peptide-Phe175+Val-peptide | P | Tyr | Glu | Glu | Phe | Val | Gln | Met | Met | Tomasselli et al., 1991 | 26104 | ||
| calmodulin | P62157 | 2-149 | peptide-Glu79+Ala-peptide | P | Asn | Pro | Thr | Glu | Ala | Glu | Leu | Gln | Tomasselli et al., 1991 | 26105 | ||
| calmodulin | P62157 | 2-149 | peptide-Gly95+Thr-peptide | P | Asp | Gly | Asn | Gly | Thr | Ile | Asp | Phe | Tomasselli et al., 1991 | 26106 | ||
| calmodulin | P62157 | 2-149 | peptide-Ala136+Ala-peptide | P | Tyr | Ile | Ser | Ala | Ala | Glu | Leu | Arg | Tomasselli et al., 1991 | 26107 | ||
| calmodulin | P62157 | 2-149 | peptide-Met143+Thr-peptide | P | Arg | His | Val | Met | Thr | Asn | Leu | Gly | Tomasselli et al., 1991 | 26108 | ||
| HIV-1 gag polyprotein junction B-based peptide | Lys-Ala-Arg-Val-Nle+Nph-Glu-Ala-Nle-NH2 | P | Ala | Arg | Val | Nle | Nph | Glu | Ala | Nle | Dunn, 2004 | |||||
| HIV-1 gag polyprotein MA/CA junction-based peptide 1 | Tyr-Val-Ser-Gln-Asn-Phe+Pro-Ile-Val-Gln-Asn-Arg | P | Ser | Gln | Asn | Phe | Pro | Ile | Val | Gln | Dunn, 2004 | |||||
| HIV-1 gag polyprotein MA/CA junction-based peptide 2 | Ser-Gln-Asn-Tyr+Pro-Ile-Val-Gln | P | Ser | Gln | Asn | Tyr | Pro | Ile | Val | Gln | Dunn, 2004 | |||||
| insulin B-chain (oxidized) | P01317 | 25-54 | Phe-Val-Asn-Gln-His-Leu-Cya-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cya+Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala | N | Tyr | Leu | Val | Cya | Gly | Glu | Arg | Gly | Tomasselli et al., 1991 | 26109 | ||
| interleukin-1 beta precursor | P01584 | 1-269 | peptide-Phe23+Phe-peptide | N | Asp | Asp | Leu | Phe | Phe | Glu | Ala | Asp | Tomasselli et al., 1991 | |||
| polyadenylate-binding protein 1 | P11940 | 1-636 | peptide-Ser237+Phe-peptide | P | Gly | Phe | Val | Ser | Phe | Glu | Arg | His | Alvarez et al., 2006 | |||
| polyadenylate-binding protein 1 | P11940 | 1-636 | peptide-Met410+Ala-peptide | P | Gly | Tyr | Phe | Met | Ala | Ala | Ile | Pro | Alvarez et al., 2006 | |||
| polyadenylate-binding protein 1 | P11940 | 1-636 | peptide-Met477+Ser-peptide | P | Pro | Arg | Val | Met | Ser | Thr | Gln | Arg | Alvarez et al., 2006 | |||
| troponin C, skeletal muscle | P02585 | 2-160 | peptide-Leu96+Ala-peptide | N | Glu | Glu | Glu | Leu | Ala | Glu | Cys | Phe | Tomasselli et al., 1991 | 26079 | ||
| troponin C, skeletal muscle | P02585 | 2-160 | peptide-Leu116+Ala-peptide | N | Pro | Glu | Glu | Leu | Ala | Glu | Ile | Phe | Tomasselli et al., 1991 | |||
| Val-Ser-Ala-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Ala | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Leu-Pro-Ile-Val-Gln | peptide-Leu5+Pro-peptide | N | AA | Ser | Gln | Asn | Leu | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Met-Pro-Ile-Val-Gln | peptide-Met5+Pro-peptide | N | AA | Ser | Gln | Asn | Met | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Phe-Pro-Ile-Val-Gln | peptide-Phe5+Pro-peptide | N | AA | Ser | Gln | Asn | Phe | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Gln | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Gln | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Gln | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Gln-Asn-Tyr-Val-Ile-Val | Val-Ser-Gln-Asn-Tyr+Val-Ile-Val | N | Ser | Gln | Asn | Tyr | Val | Ile | Val | - | Dunn, 2004 | |||||
| Val-Ser-Gly-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Gly | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Leu-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Leu | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Lys-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Lys | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Phe-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Phe | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 | ||||
| Val-Ser-Val-Asn-Tyr-Pro-Ile-Val-Gln | peptide-Tyr5+Pro-peptide | N | AA | Ser | Val | Asn | Tyr | Pro | Ile | Val | Gln | Eizert et al., 2008 |
